Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman Sells 9,563 Shares

Natera, Inc. (NASDAQ:NTRA) CEO Steven Leonard Chapman sold 9,563 shares of the business’s stock in a transaction dated Monday, March 31st. The stock was sold at an average price of $138.41, for a total transaction of $1,323,614.83. Following the sale, the chief executive officer now directly owns 212,541 shares of the company’s stock, valued at approximately $29,417,799.81. The trade was a 4.31 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Steven Leonard Chapman also recently made the following trade(s):

• On Monday, March 17th, Steven Leonard Chapman sold 6,702 shares of Natera stock. The shares were sold at an average price of $146.03, for a total value of $978,693.06.
• On Wednesday, March 5th, Steven Leonard Chapman sold 87,272 shares of Natera stock. The stock was sold at an average price of $143.40, for a total value of $12,514,804.80.
• On Wednesday, January 29th, Steven Leonard Chapman sold 13,685 shares of Natera stock. The shares were sold at an average price of $165.87, for a total value of $2,269,930.95.
• On Wednesday, January 22nd, Steven Leonard Chapman sold 78,553 shares of Natera stock. The stock was sold at an average price of $164.97, for a total value of $12,958,888.41.

Natera Stock Performance

Shares of NTRA stock traded down $0.76 on Tuesday, hitting $140.65. 1,583,711 shares of the stock were exchanged, compared to its average volume of 1,370,306. The firm’s 50 day moving average is $158.72 and its two-hundred day moving average is $151.35. Natera, Inc. has a one year low of $83.13 and a one year high of $183.00. The firm has a market capitalization of $19.01 billion, a PE ratio of -79.91 and a beta of 1.80. The company has a current ratio of 4.39, a quick ratio of 4.23 and a debt-to-equity ratio of 0.33.

Natera (NASDAQ:NTRA) last issued its earnings results on Thursday, February 27th. The medical research company reported ($0.41) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.01. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The firm had revenue of $476.10 million during the quarter, compared to analyst estimates of $447.91 million. Sell-side analysts expect that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Natera

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. LRI Investments LLC purchased a new position in shares of Natera in the fourth quarter valued at $29,000. Blue Trust Inc. grew its holdings in Natera by 104.3% during the 4th quarter. Blue Trust Inc. now owns 190 shares of the medical research company’s stock valued at $30,000 after buying an additional 97 shares in the last quarter. Versant Capital Management Inc increased its position in shares of Natera by 345.8% during the fourth quarter. Versant Capital Management Inc now owns 214 shares of the medical research company’s stock valued at $34,000 after buying an additional 166 shares during the period. EverSource Wealth Advisors LLC increased its position in shares of Natera by 372.9% during the fourth quarter. EverSource Wealth Advisors LLC now owns 331 shares of the medical research company’s stock valued at $52,000 after buying an additional 261 shares during the period. Finally, Principal Securities Inc. lifted its holdings in shares of Natera by 20.7% in the fourth quarter. Principal Securities Inc. now owns 344 shares of the medical research company’s stock worth $54,000 after buying an additional 59 shares in the last quarter. Institutional investors own 99.90% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have issued reports on NTRA. Sanford C. Bernstein lifted their price objective on shares of Natera from $160.00 to $200.00 and gave the stock an “outperform” rating in a report on Friday, January 10th. Royal Bank of Canada assumed coverage on shares of Natera in a report on Thursday, March 13th. They set an “outperform” rating and a $251.00 price target on the stock. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $180.00 price objective on shares of Natera in a research report on Wednesday, February 26th. Barclays started coverage on shares of Natera in a research report on Thursday, January 23rd. They set an “overweight” rating and a $200.00 target price on the stock. Finally, BTIG Research reaffirmed a “buy” rating on shares of Natera in a report on Friday, February 28th. One investment analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $178.12.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.